• Suzhou Ribo Life Science reached a first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals.
• The program targets liver diseases, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH).
• IND-enabling studies are set to start immediately to support planned clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260702-12225235), on July 02, 2026, and is solely responsible for the information contained therein.